146 related articles for article (PubMed ID: 38069034)
41. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
[TBL] [Abstract][Full Text] [Related]
42. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.
Fuchs BC; Finger RE; Onan MC; Bode BP
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C55-63. PubMed ID: 17329400
[TBL] [Abstract][Full Text] [Related]
43. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
[TBL] [Abstract][Full Text] [Related]
44. Equilibrative nucleoside transporter 3 promotes the progression of hepatocellular carcinoma by regulating the AKT/mTOR signaling pathway.
Qin P; Yan J; Huang H; Wang Q; Li M; Zhang Y; Wang J; Jiang T; Zhang X; Zhou Y
Int J Biol Macromol; 2023 Jun; 241():124323. PubMed ID: 37023875
[TBL] [Abstract][Full Text] [Related]
45. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].
Shang L; Jiang W; Zhang J; Wu W
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):665-672. PubMed ID: 35673909
[TBL] [Abstract][Full Text] [Related]
46. HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT.
Noh JH; Bae HJ; Eun JW; Shen Q; Park SJ; Kim HS; Nam B; Shin WC; Lee EK; Lee K; Jang JJ; Park WS; Lee JY; Nam SW
Cancer Res; 2014 Mar; 74(6):1728-38. PubMed ID: 24448241
[TBL] [Abstract][Full Text] [Related]
47. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
Sun D; Liu H; Dai X; Zheng X; Yan J; Wei R; Fu X; Huang M; Shen A; Huang X; Ding J; Geng M
Cancer Lett; 2017 Oct; 406():105-115. PubMed ID: 28687354
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
49. Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.
Yen CH; Lu YC; Li CH; Lee CM; Chen CY; Cheng MY; Huang SF; Chen KF; Cheng AL; Liao LY; Lee YH; Chen YM
Mol Med; 2012 Mar; 18(1):286-96. PubMed ID: 22160218
[TBL] [Abstract][Full Text] [Related]
50. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
51. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
[TBL] [Abstract][Full Text] [Related]
52. Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma.
Zhang T; Cui Y; Wu Y; Meng J; Han L; Zhang J; Zhang C; Yang C; Chen L; Bai X; Zhang K; Wu K; Sack MN; Wang L; Zhu L
Clin Transl Med; 2022 May; 12(5):e852. PubMed ID: 35538890
[TBL] [Abstract][Full Text] [Related]
53. Naa20, the catalytic subunit of NatB complex, contributes to hepatocellular carcinoma by regulating the LKB1-AMPK-mTOR axis.
Jung TY; Ryu JE; Jang MM; Lee SY; Jin GR; Kim CW; Lee CY; Kim H; Kim E; Park S; Lee S; Lee C; Kim W; Kim T; Lee SY; Ju BG; Kim HS
Exp Mol Med; 2020 Nov; 52(11):1831-1844. PubMed ID: 33219302
[TBL] [Abstract][Full Text] [Related]
54. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.
Ji J; Tang J; Deng L; Xie Y; Jiang R; Li G; Sun B
Oncotarget; 2015 Dec; 6(40):42813-24. PubMed ID: 26540343
[TBL] [Abstract][Full Text] [Related]
55. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
[TBL] [Abstract][Full Text] [Related]
56. HOXB13 facilitates hepatocellular carcinoma progression by activating AKT/mTOR signaling pathway.
Li M; Tan T; Geng Y; Tao Y; Pan J; Zhang J; Xu Q; Shen H; Zuo L; Chen Y
Ann Hepatol; 2023; 28(1):100759. PubMed ID: 36179794
[TBL] [Abstract][Full Text] [Related]
57. Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway.
Cai T; Bai J; Tan P; Huang Z; Liu C; Wu Z; Cheng Y; Li T; Chen Y; Ruan J; Gao L; DU Y; Fu W
Oncol Res; 2023; 31(5):805-817. PubMed ID: 37547758
[TBL] [Abstract][Full Text] [Related]
58. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
[TBL] [Abstract][Full Text] [Related]
59. NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway.
Zhao R; Ge Y; Gong Y; Li B; Xiao B; Zuo S
Aging (Albany NY); 2022 Nov; 14(22):9000-9019. PubMed ID: 36374212
[TBL] [Abstract][Full Text] [Related]
60. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
